- €771.69m
- €704.43m
- $376.13m
Brief: Pharming Group 9M Net Income USD 18.9 Mln
Pharming shares rise after preliminary Q3 revenue beat
Brief: Pharming Group Q3 Total Revenues Up At $117.6 Mln
Brief: Pharming Presents Positive Phase II Topline Data For Leniolisib
Brief: Pharming Announces Fabrice Chouraqui Will Step Down As CEO And Executive Director Effective Immediately
Brief: Pharming Announces US FDA Acceptance Of Snda For Lower Doses Of Joenja
Brief: Pharming Group Announces Positive Phase II Topline Data For Leniolisib In Pids With Immune Dysregulation
Brief: Pharming Group N.V. Newly Approved Joenja Doses Are Expected To Be Available In October
Brief: FDA Approves Joenja (Leniolisib) As First Treatment For APDS In Children Aged 4-11 Years
Netherlands' Pharming Q2 revenue falls 3%, cuts 2026 outlook
Brief: Pharming Group H1 Operating Profit USD -3.6 Million
Pharming shares plunge on declining Ruconest sales
Netherlands' Pharming Group prelim Q1 revenue falls on lower RUCONEST sales
Brief: Pharming Group Q1 Net Income USD -5.2 Million
Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pfizer's Hympavzi
Brief: Pharming Group NV Receives Positive CHMP Opinion for Joenja
Brief: Pharming Group Annouces Approval of Activated Phosphoinositide 3-Kinase Delta Syndrome Treatment In Japan
Brief: Pharming Group Eyes 2026 Total Revenues Between $405-425 MILLION
Netherlands' Pharming 2025 revenue rises on higher volumes, pricing